Results of the PROVE3 trial found that drug regimens using telaprevir were more effective against Hepatitis C than regimens without telaprevir in both treatment naïve patients and previous treatment non-responders.
Mid-stage trial notes efficacy in investigational hepatitis C treatment
By Alaric DeArment
CORK, Ireland (Apr. 9) Patients with chronic genotype 1 hepatitis C fared better when given an investigational drug developed by Johnson & Johnson division Tibotec and Vertex Pharmaceuticals than when given the standard therapy, after they had failed previous treatments, according to results of a mid-stage trial published Thursday.
The results of the 453-patient, phase 2 “PROVE3” trial, published in the New England Journal of Medicine, found that regimens based on the drug telaprevir worked better than other drugs at keeping the virus undetectable in the bloodstream.
Continue reading this entire article:
http://drugstorenews.com/story.aspx?id=136035&menuid=345